Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798458 · ClinicalTrials.gov registry record · NA
Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
A NA study of Fabry's Disease, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT02798458 is a NA study of Fabry's Disease that has completed, run by Massachusetts General Hospital. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02798458, a NA study of Fabry's Disease, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients will undergo a SmartPill test to gain additional understanding of Fabry disease manifestation via motility abnormalities in order to improve symptom targeted therapy. An additional Endoscopic mucosal resection may be performed on further qualifying patients. Tissue analysis from this biopsy will include evaluation of abnormalities of cellular structure and morphology with correlation with gastrointestinal complaints for each patient and comparison against age matched non-Fabry patient tissue. The hypothesis is that patients with fabry disease will have abnormal motility which will correlate with the patients symptoms and quality of life as noted on the questionnaires.
Conditions Studied
Interventions
- PROCEDURE Endoscopic Mucosal Resection
- DEVICE Smartpill
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-05 |
| Est. Completion | 2022-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798458
The ClinicalTrials.gov registry entry for NCT02798458 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fabry's Disease appearing as the primary indexed condition, and to 2 interventions - of which Endoscopic Mucosal Resection is the first listed.
NCT02798458 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02798458 about?
NCT02798458 is a clinical study titled "Evaluation of the Gastrointestinal Manifestation of Fabry's Disease". Patients will undergo a SmartPill test to gain additional understanding of Fabry disease manifestation via motility abnormalities in order to improve symptom targeted therapy. An additional Endoscopic mucosal resection may be performed on further qualifying patients. Tissue analysis from this biopsy...
What is the current status of trial NCT02798458?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2016-05. Estimated completion is 2022-11.
What conditions does trial NCT02798458 study?
This clinical trial studies the following conditions: Fabry's Disease.
What interventions are being tested in trial NCT02798458?
The interventions under investigation include: Endoscopic Mucosal Resection (PROCEDURE), Smartpill (DEVICE).
Who is sponsoring clinical trial NCT02798458?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02798458 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.